AMAG Pharmaceuticals, Inc. Announces First Quarter 2012 Financial Results

LEXINGTON, Mass.--(BUSINESS WIRE)--AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a specialty pharmaceutical company focused on the development and commercialization of Feraheme® (ferumoxytol) Injection for intravenous (IV) use to treat iron deficiency anemia (IDA), today reported unaudited consolidated financial results for the first quarter ended March 31, 2012. As of March 31, 2012, the company’s cash, cash equivalents and investments totaled approximately $218 million.